Actinium Pharmaceuticals Announces Positive Safety and Efficacy Results From Phase 1 Actimab-A Trial in Patients With Newly Diagnosed Acute Myeloid Leukemia and Provides Guidance on Plans for Phase 2 Clinical Trial Jun 1, 2016
Actinium Announces Webinar to Discuss Results of the Actimab-A Phase 1 Trial and Key Findings From the HuM195-Alpha Program May 18, 2016
Actinium to Present at BIO International Convention and Provide Updates on Actimab-A and Iomab-B Programs May 10, 2016
Actinium to Host Webinar to Discuss SIERRA Trial -- Upcoming Pivotal, Phase 3 Clinical Study for Iomab-B Apr 25, 2016
UPDATE - Actinium Announces Selection of Zevacor Pharma, Inc. for Clinical Production and Supply of Iomab-B for Pivotal Phase 3 SIERRA Trial Apr 12, 2016
Actinium Announces Selection of Zevacor Pharma, Inc. for Clinical Production and Supply of Lomab-B for Pivotal Phase 3 SIERRA Trial Apr 12, 2016
Actinium Announces Webinar to Discuss SIERRA Trial -- Upcoming Pivotal, Phase 3 Clinical Study for Iomab-B Apr 6, 2016
Actinium Further Strengthens Clinical Development Team With Hiring of Director of Clinical Operations Mar 31, 2016
Actinium Receives Orphan Drug Designation From FDA for Iomab-B in Treating Refractory and Relapsed Acute Myeloid Leukemia in Elderly Patients Mar 30, 2016
